- Home
- PRTC vs BME Comparison
PRTC vs BME Comparison
Compare PRTC & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- BME
- Stock Information
- Founded
- PRTC 2015
- BME 2005
- Country
- PRTC United States
- BME United States
- Employees
- PRTC N/A
- BME N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- BME Trusts Except Educational Religious and Charitable
- Sector
- PRTC Health Care
- BME Finance
- Exchange
- PRTC Nasdaq
- BME Nasdaq
- Market Cap
- PRTC 439.8M
- BME 462.3M
- IPO Year
- PRTC N/A
- BME N/A
- Fundamental
- Price
- PRTC $17.90
- BME $35.51
- Analyst Decision
- PRTC Buy
- BME
- Analyst Count
- PRTC 1
- BME 0
- Target Price
- PRTC $45.00
- BME N/A
- AVG Volume (30 Days)
- PRTC 2.0K
- BME 34.0K
- Earning Date
- PRTC 04-30-2025
- BME 01-01-0001
- Dividend Yield
- PRTC N/A
- BME 6.26%
- EPS Growth
- PRTC N/A
- BME N/A
- EPS
- PRTC 0.21
- BME 1.44
- Revenue
- PRTC $4,828,000.00
- BME N/A
- Revenue This Year
- PRTC $35.98
- BME N/A
- Revenue Next Year
- PRTC $115.38
- BME N/A
- P/E Ratio
- PRTC $7.81
- BME $28.37
- Revenue Growth
- PRTC 44.98
- BME N/A
- 52 Week Low
- PRTC $13.30
- BME $35.53
- 52 Week High
- PRTC $28.39
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- PRTC 46.07
- BME 39.79
- Support Level
- PRTC $19.00
- BME $35.60
- Resistance Level
- PRTC $19.80
- BME $36.71
- Average True Range (ATR)
- PRTC 0.33
- BME 0.36
- MACD
- PRTC -0.12
- BME -0.04
- Stochastic Oscillator
- PRTC 16.30
- BME 6.25
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.